IOVANCE BIOTHERAPEUTICS INC (IOVA) competitors & alternatives
Health Care · NASDAQ
IOVANCE BIOTHERAPEUTICS INC (IOVA)'s top competitors and alternatives — its most similar public companies — include Bristol Myers Squibb (BMY), Genelux Corp (GNLX), ARRIVENT BIOPHARMA INC (AVBP), Summit Therapeutics (SMMT), BLACK DIAMOND THERAPEUTICS INC (BDTX), BridgeBio Oncology Therapeutics, Inc. (BBOT), MACROGENICS INC (MGNX), NOVOCURE LTD (NVCR), IMMUNITYBIO INC (IBRX), CANDEL THERAPEUTICS INC (CADL), CRESCENT BIOPHARMA INC (CBIO) and NUVALENT INC CLASS A (NUVL). These are IOVANCE BIOTHERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top IOVA competitors & alternatives
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
Genelux CorpGNLXHealth Care
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and…
$2.96 (as of 2026-07-22) · market cap $131M
-
ARRIVENT BIOPHARMA INCAVBPHealth Care
Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung…
$30.44 (as of 2026-07-22) · market cap $1.3B
-
Summit TherapeuticsSMMTHealth Care
Oncology-focused biotech developing ivonescimab, a first-in-class bispecific antibody combining PD-1 immunotherapy with anti-VEGF anti-angiogenesis, with Phase…
$14.74 (as of 2026-07-22) · market cap $11.4B
-
BLACK DIAMOND THERAPEUTICS INCBDTXHealth Care
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey inhibitors designed to target families of oncogenic mutations across…
$1.83 (as of 2026-07-22) · market cap $106M
-
BridgeBio Oncology Therapeutics, Inc.BBOTHealth Care
BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including…
$8.90 (as of 2026-07-22) · market cap $701M
-
MACROGENICS INCMGNXHealth Care
Clinical-stage biopharmaceutical company developing innovative antibody-based cancer therapeutics using proprietary DART, TRIDENT, and ADC platforms.
$4.30 (as of 2026-07-22) · market cap $289M
-
NOVOCURE LTDNVCRHealth Care
Novocure delivers Tumor Treating Fields therapy through wearable medical devices to treat aggressive cancers including glioblastoma, lung cancer, and…
$15.57 (as of 2026-07-22) · market cap $1.8B
-
IMMUNITYBIO INCIBRXHealth Care
ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to…
$7.51 (as of 2026-07-22) · market cap $8.0B
-
CANDEL THERAPEUTICS INCCADLHealth Care
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic…
$10.09 (as of 2026-07-22) · market cap $739M
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
NUVALENT INC CLASS ANUVLHealth Care
Nuvalent is a clinical-stage precision oncology company developing targeted kinase inhibitors to address the challenges of treatment resistance and off-target…
$123.96 (as of 2026-07-21) · market cap $9.8B
Not quite? Describe exactly what you want →
Peers are IOVANCE BIOTHERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: IOVANCE BIOTHERAPEUTICS INC (IOVA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.